De Motu Cordis Highlighted in Two Page Feature in the Courier Mail
March 18, 2025
De Motu Cordis are proud to be featured in the Saturday edition of the Courier Mail (March 15th, 2025).
Senior reporter, Rachel Riley, visited the De Motu Cordis Windsor Head Office to meet with the team. On the day, she toured the onsite pilot production facility, learnt about the dry powder inhaler platform and product development to date. This included product stability data which currently shows potential for an impressive shelf life.
Detail on the clinical program conducted to date was also presented along with DMC’s plans, currently underway, for a further pilot trial in allergy patients, a first for the company.
CEO, Peter O’Neill shared plans for an upcoming capital raise to ensure the ongoing development of the inhaler platform, whilst Prof. John Fraser AO gave his vision for building biotech manufacturing capabilities here in QLD with the help of local funding.
All these topics and more are covered in detail in the Courier Mail article attached below for viewing.
About DMC
DMC is a clinical stage medtech company founded in Brisbane, Australia by globally recognised intensive care specialist, researcher, entrepreneur and founder Professor John Fraser AO.
DMC is developing a proprietary inhaled drug delivery platform for use in critical care emergencies. Our lead asset is an investigational inhaled epinephrine product to treat anaphylaxis.
DMC has a strong suite of intellectual property portfolio protecting both its inhaled drug delivery platform and therapeutic formulations. To date, DMC has raised more than AU$30 million from both private and public sector investors.
